Navigation Links
Resverlogix is Presenting at IAS HDL Workshop
Date:10/11/2007

Novel ApoA-I/HDL raising drug, RVX-208, to be featured in oral presentation

TSX Exchange Symbol: RVX

CALGARY, Oct. 11 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that tomorrow it is making an oral presentation highlighting key scientific data of its lead clinical molecule, RVX-208, at the International Atherosclerosis Society (IAS) Workshop on HDL. The presentation titled "A novel drug that raises apolipoprotein A-I and HDL in vitro and in vivo" will be presented by Dr. Norman Wong, Resverlogix Co-Founder and Chairman of the Scientific Advisory Board on October 12th at the Petros M. Nomikos Conference Center in Santorini, Greece.

"This meeting of the IAS attracts internationally elite scientists in cardiovascular medicine. This venue is ideal for announcing the favorable and novel features of RVX-208, scheduled for clinical trials later this year," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. Dr. Johansson added, "RVX-208 is a small molecule for oral administration that has shown to have unprecedented effects in raising ApoA-I and functional HDL. There is an ever-increasing body of evidence from predictive animal models that indicates RVX-208's potential for preventing and regressing atherosclerosis. We are very happy to participate in this important conference."

Mr. Donald McCaffrey, President and CEO of Resverlogix said, "These highly regarded researchers who will be participating at the event clearly understand that there is a large unmet medical need in cardiovascular disease (CVD). There is a lot of excitement among these key opinion leaders that Resverlogix's novel small molecule drug could address many of the shortcomings of current CVD drugs."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that

reflect the current views and/or expectations of Resverlogix Corp. with

respect to its performance, business and future events. Such statements

are subject to a number of risks, uncertainties and assumptions. Actual

results and events may vary significantly. The TSX Exchange does not

accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 2016 , ... In a list published by the Boston Business Journal, ... companies; a small percentage of the state's 615,000+ small businesses. The list examined companies ... revenue from 2012 to 2015. , As this award comes on the ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... addition of Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently ... as Corporate Executive Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... the sensor and data driven conferences, will take place on June 7-8, 2016, at the New ... Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI ...
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
Breaking Biology Technology:
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
(Date:3/14/2016)... March 14, 2016 http://www.apimages.com ... --> - Renvoi : image disponible via ... --> --> DERMALOG, le ... de nouveaux lecteurs d,empreintes digitales pour l,enregistrement des ... sera utilisé pour produire des cartes d,identité aux ...
Breaking Biology News(10 mins):